MDM2 Inhibitors for Pancreatic Cancer Therapy

E-ISSN： 1875-5607|10|6|518-526

ISSN： 1389-5575

Source： Mini Reviews in Medicinal Chemistry, Vol.10, Iss.6, 2010-06, pp. : 518-526

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Reactivation of p53 by Novel MDM2 Inhibitors: Implications for Pancreatic Cancer Therapy

Current Cancer Drug Targets, Vol. 10, Iss. 3, 2010-05 ,pp. : 319-331

Bentham Science Publishers

Access to resources Recommend Favorite

Emerging cell-cycle inhibitors for pancreatic cancer therapy

By Bayraktar Soley

Expert Opinion on Emerging Drugs, Vol. 17, Iss. 4, 2012-12 ,pp. : 571-582

Informa Healthcare

Access to resources Recommend Favorite

Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011 – present)

By Zak Krzysztof Pecak Aleksandra Rys Barbara Wladyka Benedykt Dömling Alexander Weber Lutz Holak Tad A Dubin Grzegorz

Expert Opinion on Therapeutic Patents, Vol. 23, Iss. 4, 2013-04 ,pp. : 425-448

Informa Healthcare

Access to resources Recommend Favorite

Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?

Current Medicinal Chemistry, Vol. 21, Iss. 5, 2014-02 ,pp. : 553-574

Bentham Science Publishers

Access to resources Recommend Favorite

p53-Independent Activities of MDM2 and Their Relevance to Cancer Therapy

Current Cancer Drug Targets, Vol. 5, Iss. 1, 2005-02 ,pp. : 9-20

Bentham Science Publishers

Access to resources Recommend Favorite